Fig. 1

Study design. *Powder dissolved in hot water. ^aMedical history recorded was any existing or resolved condition that started prior to informed consent. Changes in the medical history were assessed at visit 2 (day 1). ^bFull physical examination occurred on visit 1 screening and on visit 2 (day − 1). A brief physical examination occurred on visit 2 (day 1) before randomization and prior to discharge. ^cVital signs performed at visit 1 and visit 2 (day − 1) included BP, RR, PR, and oral temperature. At visit 2 (day 1), vital signs included BP and PR performed before randomization and after the last scintigraphic image was obtained. ^dAEs (serious and non-serious) were collected from the time the subject signed the informed consent form until 5 days following the last administration of the investigational product. ^eSubjects were given a standard lunch 4 h post-dose and a standard dinner 10 h post-dose. ^fFasting occurred from 10 h prior until 4 h after study drug administration. ^gLaboratory tests on visit 2 (day 1) were conducted after the final scintigraphic image was taken, prior to dinner. ^eScintigraphic acquisitions were taken beginning after dose administration until 10 h post-dose. AEs, adverse events; BP, blood pressure; ECG, electrocardiogram; PR, pulse rate, RR, respiratory rate